Celldex Therapeutics (CLDX) EBT Margin Growth (1y) (2011 - 2026)

Celldex Therapeutics (CLDX) EBT Margin Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (1y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1,526.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1,558.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -683.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 813.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Celldex Therapeutics 2.34 Bn 2.34 Bn -1.44 Mn -56.37 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -56.37 Mn
Dec 31, 2025 -6.16 Mn
Jun 30, 2025 -688,418.00
Mar 31, 2025 1.81 Mn
Dec 31, 2024 -1.95 Mn
Sep 30, 2024 122,098.00
Jun 30, 2024 1.07 Mn
Mar 31, 2024 -2.38 Mn
Dec 31, 2023 -781,547.00
Sep 30, 2023 383,594.00
Jun 30, 2023 948,275.00
Mar 31, 2023 992,344.00
Dec 31, 2022 439,024.00
Sep 30, 2022 693,485.00
Jun 30, 2022 -2.17 Mn
Mar 31, 2022 -1.08 Mn
Dec 31, 2021 -542,909.00
Sep 30, 2021 -1.14 Mn
Jun 30, 2021 438,648.00
Mar 31, 2021 -169,825.00